1. CCN5/WISP-2: A micromanager of breast cancer progression

   • Sushanta K. Banerjee
   • Snigdha Banerjee

   Review 10 April 2012 Pages: 63 - 71

   

2. CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis

   • Véronique Ouellet
   • Peter M. Siegel

   Review Open access 18 March 2012 Pages: 73 - 85

   

3. Analysis of the MMP-dependent and independent functions of tissue inhibitor of metalloproteinase-2 on the invasiveness of breast cancer cells

   • Logan A. Walsh
   • Mario A. Cepeda
   • Sashko Damjanovski

   Research Article 08 January 2012 Pages: 87 - 95

   

4. Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis

   • Bruce L. Riser
   • Narasimharao Bhagavathula
   • James Varani

   Research Article 31 May 2012 Pages: 97 - 105

   

5. A proposal of an in vitro model which mimics in situ areas of carcinoma

   • Elizabeth F. Martinez
   • Pollyanna T. Montaldi
   • Vera C. de Araújo

   Report 16 February 2012 Pages: 107 - 109

   

6. Egr-ly awaiting a “personalized medicine” approach to treat scleroderma

   • Andrew Leask

   Bits and Bytes 15 February 2012 Pages: 111 - 113

7. CCN3: a novel anti-fibrotic treatment in end-stage renal disease?

   • Andrew Leask

   Bits and Bytes 16 March 2012 Pages: 115 - 116

8. CCN3: the-pain-killer inside me

   • Bernard Perbal
   • International CCN Society

   Bits and Bytes 30 March 2012 Pages: 117 - 120